

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
01 September 2022 (01.09.2022)



(10) International Publication Number
WO 2022/180500 A2

(51) International Patent Classification:
C07K 14/005 (2006.01)

(21) International Application Number:
PCT/IB2022/051504

(22) International Filing Date:
21 February 2022 (21.02.2022)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/153,164 24 February 2021 (24.02.2021) US
63/306,669 04 February 2022 (04.02.2022) US

(71) Applicant: **PFIZER INC.** [US/US]; 235 East 42nd Street,
New York, New York 10017 (US).

(72) Inventors: **CHI, Xiaoyuan Sherry**; 210 Jefferson Avenue,
Tenaflly, New Jersey 07670 (US). **DORMITZER, Philip
Ralph**; 73 Old Orchard Road, Sherborn, Massachusetts
01770 (US). **LIU, Weifeng**; c/o Pfizer Inc., 401 N. Mid-
dletown Road, Pearl River, New York 10965 (US). **LIU,
Yuhang**; c/o Pfizer Inc., 445 Eastern Point Road, Building
98, Groton, Connecticut 06340 (US).

(74) Agent: **ZIELINSKI, Bryan C.**; Pfizer Inc., 100 Route 206
North, Mail Stop: SOM-PPK4-LLA-403, Peapack, New
Jersey 07977 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JM, JO, JP, KE, KG, KH,
KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA,
MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI,
NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU,
RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM,
ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

(54) Title: NOVEL DRUGGABLE REGIONS IN THE HUMAN CYTOMEGALOVIRUS GLYCOPROTEIN B POLYPEPTIDE
AND METHODS OF USE THEREOF

FIG. 21A



(57) Abstract: The present invention relates to a method for identifying a candi-
date therapeutic for a disease caused by infection with a human cytomegalovirus
(HCMV) having a glycoprotein B (gB) polypeptide, comprising contacting the
HCMV gB polypeptide comprising a druggable region with a compound, where-
in binding of said compound indicates a candidate therapeutic. The present inven-
tion also relates to candidate therapeutics comprising modulators and inhibitors of
HCMV activity and pharmaceutical compositions comprising said modulators and
inhibitors and methods of use thereof.

WO 2022/180500 A2

[Continued on next page]

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *without international search report and to be republished upon receipt of that report (Rule 48.2(g))*
- *with sequence listing part of description (Rule 5.2(a))*
- *in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE*